Held by 6 specialist biotech funds
High Convergence**Signal Note: Perceptive Advisors Initiates $53.8M Position in Invivyd** Edelman's new stake signals conviction in Invivyd's RSV monoclonal antibody platform, likely driven by upcoming Phase 2b data for IV-D in immunocompromised patients (expected late 2024/early 2025) and commercial potential in a market validated by GSK's Arexvy approval.
AI analyst context — unlock full analysis
# Signal Note: BVF Partners Initiates $48.2M Position in Invivyd BVF's entry into IVVD signals conviction in the company's RSV monoclonal antibody platform, particularly ahead of potential label expansions beyond its current immunocompromised adult indication. The 19.5M share stake (likely 5-10% ownership) suggests Lampert sees value in pipeline catalysts—including pediatric and elderly population data that could significantly expand TAM for respiratory syncytial virus prophylaxis. Timing likely correlates with near-term clinical readouts or regulatory feedback that de-risks commercial assumptions.
+ 4 more positions with dollar amounts and AI context
Unlock All — 7-Day Free Trial